JPRN-jRCT2080224816已完成2 期
A randomized, double-masked, placebo-controlled study of DE-127 ophthalmic solution in subjects with myopia - A Phase II/III, Confirmatory Study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 5age old 至 <= 15age old（—）
- 性别
- All
入选标准
- •Written informed consent from legally acceptable representative and assent from subject have been obtained.
- •- Cycloplegic objective spherical equivalent -1.0 to -6.0 D
- •- Active myopia progression with vision acuity test
排除标准
- •- Patients who previously used contact lenses and/or treatments for reducing myopia progression.
- •- Patients who previously participated in a clinical trial of DE-127 ophthalmic solution.
- •- Other patients who are inappropriate as participants in this study in the opinion of the investigator or subinvestigator.
研究者
相似试验
进行中（未招募）
1 期
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisEUCTR2012-001125-27-GBInstitut de Recherches Internationales Servier84
进行中（未招募）
不适用
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisEUCTR2012-001125-27-GRInstitut de Recherches Internationales Servier110
进行中（未招募）
不适用
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisBehçet?s disease uveitisMedDRA version: 14.1Level: LLTClassification code 10071139Term: Behcet's uveitisSystem Organ Class: 100000004870EUCTR2012-001125-27-ESaboratorios Servier S.L.110
进行中（未招募）
1 期
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisBehçet’s disease uveitisMedDRA version: 18.0Level: LLTClassification code 10071139Term: Behcet's uveitisSystem Organ Class: 100000004866EUCTR2012-001125-27-PTInstitut de Recherches Internationales Servier44
进行中（未招募）
不适用
Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitisEUCTR2012-001125-27-DEInstitut de Recherches Internationales Servier44